SEP 0 6 2005



PTO/SB/21 (09-04)
Approved for use through 07/31/2006, OMB 0651-0031

at the Ro	nonwork Poductio	n Act of 1005	no comon	U.S	6. Patent and T	Approved Frademark (	Office; t	J.S. DEPARTMENT OF COMMERCE	
ACT OF 1993 NO DEISO			. Ho belson	Application Number	09/320,17	Patent and Trademark Office; U.S. DEPARTMENT OF COMMI lection of information unless it displays a valid OMB control nu 09/320,172			
TRANSMITTAL FORM				Filing Date	May 26, 1	May 26, 1999 SHMULEWITZ et al.			
				First Named Inventor	SHMULE				
			Art Unit	3763	3763				
(to be used for all correspondence after initial filing)			filing)	Examiner Name	MENDEZ,	MENDEZ, Manuel A.			
Total Number of Pages in This Submission				Attorney Docket Number	PA2035 C	2035 CIP2			
ENCLOSURES (Check all that apply)									
Fee Attached  Amendment/Reply After Final Affidavits/declaration(s)  Extension of Time Request Express Abandonment Request			rawing(s) icensing-related Papers etition etition to Convert to a rovisional Application ower of Attorney, Revocation change of Correspondence Address erminal Disclaimer tequest for Refund ED, Number of CD(s) Landscape Table on CD		After Allowance Communication to TC  Appeal Communication to Board of Appeals and Interferences  Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please Identify below):  Return Postcard				
Document(s)  Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT									
Firm Name Medtronic Vascular, Inc.									
Signature	7//	1 1	1						
Printed name									
Michael J. Jaro									
Date September 2, 2005				Reg. No. 34			34,472		
CERTIFICATE OF TRANSMISSION/MAILING  I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:									
Signature	1	Ki	1	<u>.</u>					
Typed or printed name Kimberly M		erly Melvin	vin				Date	September 2, 2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## CERTIFICATE OF MAILING (37 C.F.R. § 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in the envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2313-1450 on September 2,2005.

By: Kimberly Melvin

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

09/320,172

Confirmation No.:

4246

**Applicant** 

SHMULEWITZ, et al.

Filed

May 26, 1999

TC/A.U.

3763

Examiner

MENDEZ, Manuel A

Docket No.

PA 2035 CIP2

Customer No.

28390

Title

APPARATUS FOR PROVIDING CORONARY

RETROPERFUSION AND METHODS OF USE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **AMENDMENT**

Sir:

In response to the Office Action dated June 3, 2005, please amend the above-identified application as set forth below. Favorable consideration and entry of this amendment is respectfully requested.

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 8 of this paper.